The primary objective of this study is to evaluate a range of dose levels for efficacy in the control of symptoms of allergic rhinitis
This will be a randomised, double blind, placebo controlled, parallel group evaluation of OC000459 given orally for eight days. Four dose levels will be studied and compared to placebo. They will be studied in treatment groups of 18 to 21 subjects. The placebo group will also consist of 18 to 21 subjects. There will be a screening period of up to six weeks. There will be a follow up one to three weeks after the last dose of study drug.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
120
Allergie Zentrum Wien West, Vienna Challenge Chamber
Vienna, Austria
Total nasal symptom score (TNSS)
Time frame: After 8 days of treatment
Other symptom scores of allergic rhinitis
Time frame: After 8 days of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Tablets twice daily for 8 days Dose level 4
Tablets twice daily for 8 days Dose level 5